"Dupilumab improved key asthma-related outcomes, suppressed type 2 inflammatory biomarkers, and improved rhinoconjunctivitis-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid PAR,” researchers wrote.
"Dupilumab improved key asthma-related outcomes, suppressed type 2 inflammatory biomarkers, and improved rhinoconjunctivitis-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid PAR,” researchers wrote.
"Dupilumab improved key...